A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
NCT05559476
Completed
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/09/2024
Locations: GSK Investigational Site, Austin, Texas +2 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2024
Locations: Tekton Research - Austin - PPDS, Austin, Texas +10 locations
Conditions: Seasonal Influenza
Register for Updates
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
NCT04707391
Completed
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
Gender:
ALL
Ages:
Between 15 years and 25 years
Trial Updated:
06/07/2024
Locations: GSK Investigational Site, Austin, Texas +8 locations
Conditions: Meningitis, Meningococcal
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
NCT05975060
Completed
This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ in previously mRNA COVID-19 vaccinated adult participants ≥18 years of age and baseline SARS CoV-2 seropositive COVID-19 vaccine naïve participants ≥18 years of age.
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
05/29/2024
Locations: Benchmark Research, Austin, Texas +6 locations
Conditions: COVID-19
Register for Updates
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
NCT05506969
Completed
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/22/2024
Locations: Optimal Research Texas, Austin, Texas
Conditions: Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Register for Updates
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
NCT00630331
Completed
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/22/2024
Locations: Site 9, Austin, Texas +1 locations
Conditions: Influenza
Register for Updates
Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
NCT05630859
Active Not Recruiting
The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/19/2024
Locations: GSK Investigational Site, Austin, Texas
Conditions: Sexually Transmitted Diseases
Register for Updates
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/01/2024
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Register for Updates
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
NCT03486834
Completed
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age. Participants received blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and were followed to approximately Month 24. The primary hypothesis of the study was that administration o... Read More
Gender:
FEMALE
Ages:
Between 16 years and 35 years
Trial Updated:
01/19/2024
Locations: Tekton Research, Inc. ( Site 0036), Austin, Texas +8 locations
Conditions: Cytomegalovirus (CMV) Infections
Register for Updates
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
NCT04816643
Completed
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age may subsequently be evaluated.
Gender:
ALL
Ages:
Between 6 months and 15 years
Trial Updated:
12/18/2023
Locations: ARC Clinical Research at Four Points, Austin, Texas +13 locations
Conditions: SARS-CoV-2 Infection, COVID-19
Register for Updates
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03673462
Completed
The primary objective of this study was to describe the safety profile of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) Conjugate Vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
12/11/2023
Locations: ARC Clinical Research at Wilson Parke-Site Number:8400071, Austin, Texas +4 locations
Conditions: Healthy Volunteers (Meningococcal Infection)
Register for Updates
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
NCT06118151
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin compared to an active control quadrivalent recombinant influenza vaccine (RIV4) in adults 18 years of age and older. Study details include: Study Duration: approximately 6 months Treatment Duration: 1 injection of mRNA vaccine encoding influenza hemagglutinin encoding influenza hemag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Elligo Health Research, Inc. Site Number : 8400035, Austin, Texas +3 locations
Conditions: Influenza, Influenza Immunization
Register for Updates